跳至主要内容
临床试验/NCT01549223
NCT01549223已完成4 期

A Randomized Controlled Trial of Standardized Versus Conventional Oxytocin and Uterotonic Agent Use for Cesarean Delivery

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2011年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
60
试验地点
1
主要终点
1. Amount of Oxytocin to Obtain Satisfactory Uterine Tone.

研究概览

简要总结

The central objective of this study will be to evaluate a standardized, evidence-based regimen versus a conventional regimen for uterotonic drug dosing for elective cesarean delivery

The investigators primary hypothesis is that the proposed uterotonic drug regimen, when compared to conventional dosing regimen, during elective cesarean delivery will:

  1. Reduce the overall amount of oxytocin and other uterotonic agents used to obtain satisfactory uterine tone.

Secondary outcomes to be evaluated will be:

  1. Reduce the side effects associated with uterotonic drug use
  2. Reduce the time to establishment and maintenance of adequate uterine tone

详细描述

The current guidelines for the administration of oxytocin during cesarean delivery are diverse, empiric, and vague. A stepwise, standardized, checklist driven algorithm for the use of oxytocin and other uterotonic agents during cesarean delivery is needed to guide practitioners in a clear and concise manner. This algorithm should encompass laboring and non-laboring women, as well as prophylactic and therapeutic uses of oxytocin and other uterotonic agents.

More specifically, the investigators believe that the following points should be incorporated into a protocol: 1) oxytocin should be used in initial doses of less than 5 IU; 2) oxytocin should not be administered as a rapid IV bolus; 3) an initial rapid infusion of oxytocin should be followed by a maintenance infusion; 4) higher initial and infusion doses of oxytocin offer no clinical benefit and should be avoided; and 5) if it appears that oxytocin is not producing effective uterine contractions, other uterotonic drugs acting via different pathways should be considered in a standardized way.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • American Society of Anesthesiologists (ASA) I or II health status
  • Age between 18 and 50 yrs
  • Singleton pregnancies in vertex position
  • Elective (without prior labor) cesarean delivery with a planned lower uterine (pfannenstiel) incision

排除标准

  • Conditions that predispose to uterine atony and postpartum hemorrhage

研究组 & 干预措施

Standard Care Group

Active Comparator

"Standard Care Group" (reflects current clinical regimen at BWH) will receive a 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request. The obstetrician and anesthesiologist will be asked to consider this infusion "oxytocin". If inadequate uterine tone exists in which the obstetrician desires alternative uterotonic agents, these will be provided on their request (e.g. methylergonovine maleate (methergine) 0.2 mg IM (intramuscular) or carboprost tromethamine (hemabate) 0.25 mg IM. The time of the requests will be recorded.

If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally.

干预措施: Oxytocin Infusion (Drug)

Protocol Group

Active Comparator

"Protocol Group" will receive 3 mL syringes marked "study solution-oxytocin" which contain 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).

If inadequate uterine tone is noted at 9 min, the 1 mL syringe marked marked "study solution-9 min", containing methylergonovine maleate (methergine) 0.2mg, will be given IM.

If inadequate uterine tone is noted at 12 min, the 1 mL syringe marked marked "study solution-12 min", containing carboprost tromethamine (hemabate) 0.25 mg, will be given IM.

If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally.

干预措施: Oxytocin Bolus (Drug)

结局指标

主要结局

1. Amount of Oxytocin to Obtain Satisfactory Uterine Tone.

时间窗: Up to 15 min from time of infant delivery

Will measure total amount of oxytocin to achieve satisfactory uterine tone, as determined by the operating obstetrician.

次要结局

  • Side Effects (Hypotension, Flushing, Nausea and Emesis) Associated With Uterotonic Drug Use(Up to 15 min from time of infant delivery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lawrence Ching Tsen

Vice Chair, Faculty Development and Education; Associate Professor, Harvard Medical School

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验